# Study Evaluating The Potential Effect Of Lansoprazole On The Pharmacokinetics Of Bosutinib In Healthy Subjects

> **NCT00952913** · PHASE1 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 24 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Bosutinib
- **DRUG:** Bosutinib
- **DRUG:** Lansoprazole

## Key facts

- **NCT ID:** NCT00952913
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08
- **Primary completion:** 2009-10
- **Final completion:** 2009-10
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2011-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00952913

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00952913, "Study Evaluating The Potential Effect Of Lansoprazole On The Pharmacokinetics Of Bosutinib In Healthy Subjects". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00952913. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*